ClinicalTrials.gg
RecruitingNCT05950386Updated Jul 21, 2023

Effects of Lead Exposure on Ferroptosis Pathway

An observational study in Lead Poisoning and Neurotoxicity, sponsored by Northern Jiangsu People's Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-07-21.

Sponsored by Northern Jiangsu People's Hospital · Observational

From the registry’s dates

  • Primary completion was expected by Aug 2023, 3 years 3 months ago, but the record still lists the study as recruiting.
  • Started Jul 2023; still recruiting 3 years 4 months later.
Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
40
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The aim of this study was to investigate the effects of chronic lead exposure on iron metabolism and the Nrf2-dependent ferroptosis pathway in lead acid battery factory workers

Read the detailed description

Background:

Lead (Pb) is a prevalent and highly toxic heavy metal. Human activities have been the primary cause of lead contamination in the environment over the past century. Lead exposure poses a global concern, particularly for children, and individuals can be exposed to lead through various means, such as contaminated soil, dust, food, water, or foreign objects. The central nervous system (CNS) is particularly vulnerable to the toxic effects of lead (Pb), especially in children, primarily due to the immaturity of the blood-brain barrier.

Ferroptosis is a recently defined form of regulated cell death characterized by iron-dependent cell death resulting from the accumulation of lipid hydroperoxides. However, the exact mechanism underlying the neurotoxic effects of chronic low-level lead exposure-induced ferroptosis on neuronal injury is not yet fully understood.

Methods:

The investigators first analyze the difference of blood lead level using atomic absorption spectrometry.

The investigators enrolled 20 chronic lead exposure workers from a lead acid battery factory and an age-matched control group of non-lead-exposed workers.

TNF-α elisa kit was used to compare the proinflammatory cytokines in two groups.

Quantitative reverse transcription PCR (Polymerase Chain Reaction) was used to compare messenger ribonucleic acid (mRNA) expression of iron metabolism (FTH1, FPN1, DMT1) and the Nrf2-dependent ferroptosis pathway (Nrf2, SLC7A11, GPX4)

Detailed Methods protocol

  1. The criteria of enrolled chronic lead exposure participants were as follows:inclusion: work for this lead acid battery factory more than 10 year; exclusion: exposure to any chemistry pollution before; neurological disorders; endocrine diseases; cancer
  2. Sample collection: at the end of recruitment in this study, all of the enrolled participant will come to the hospital to collect peripheral Blood (Northern Jiangsu People's Hospital, affiliated with Yangzhou University), and the blood samples will be collected into EDTA (ethyleneDiamine tetraacetic acid) vacutainer tubes and then divided into leukocytes and plasma for further experiments.
  3. TNF-α ELISA KIT: Plasma TNF-α concentrations were detected by the competitive ELISA method
  4. Primer sequence used in this study:

1.DMT1 forward: 5'-CTAGACTGGGAGTGGTTACTGG-3' DMT1 reverse: 5'-AGGATGACTCGTGGGACCTT-3' 2.FTH1 forward: 5'-CTGGTGGCCGAATCTTCCTTCA-3' FTH1 reverse: 5'-GCCAGTTTGTGCAGTTCCAG-3' 3.FPN1 forward: 5'-CTACTTGGGGAGATCGGATGT-3' FPN1 reverse: 5'-CTGGGCCACTTTAAGTCTAGC-3' 4.GPX4 forward: 5'-GAGGCAAGACCGAAGTAAACTAC-3' GPX4 reverse: 5'-CCGAACTGGTTACACGGGAA-3' 5.SLC7A11 forward: 5'-TCTCCAAAGGAGGTTACCTGC-3' SLC7A11 reverse: 5'-AGACTCCCCTCAGTAAAGTGAC-3' 6. Nrf2 forward 5'-ATAGCTGAGCCCAGTATC-3' Nrf2 reverse 5'- CATGCACGTGAGTGCTCT-3' 7. GAPDH forward: 5'-GGAGCGAGATCCCTCCAAAAT-3' GAPDH reverse: 5'-GGCTGTTGTCATACTTCTCATGG-3'

02

Conditions studied

  • Lead Poisoning
  • Neurotoxicity

Keywords

  • Ferroptosis
  • Nrf2
  • Iron metabolism
  • Lead exposure
  • Neurotoxicity
03

In context

Lead Poisoning

27 studies on the registry are indexed under Lead Poisoning; 2 are open to participants now.

This study's planned enrollment of 40 is below the median of 350 across 14 observational studies indexed under Lead Poisoning.

Browse Lead Poisoning studies →

Lead sponsor

Northern Jiangsu People's Hospital is the lead sponsor of 61 studies on the registry; 31 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The control group will be selected from the invited who live in Yangzhou city via the website, email, and poster.

The lead exposure group will be selected from the invited volunteers who live in Yangzhou with the assistance of the Center for Disease Control and Prevention of Yangzhou, the website, email, and poster.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged over 18 years old
  2. Work for the lead acid battery factory more than 10 years

Exclusion criteria

Exclusion Criteria:

  1. Neurological disorders
  2. Endocrine diseases
  3. Cancer
  4. Exposure to any chemical pollutant before
05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
40 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • The control group

    The invited non-lead-exposed workers live in Yangzhou, Jiangsu, China

  • The lead exposure group

    The invited chronic-lead exposed workers live in Yangzhou, Jiangsu, China

    Other: Lead exposure

Interventions

  • OtherLead exposure

    The lead-acid battery factory workers will exposure to lead via Inhalation of lead particles, ingestion of lead-contaminated dust and water.

06

What researchers measure

Primary outcomes

  1. Concentration of TNF-α level in peripheral blood

    Biomarkers of the proinflammatory cytokines

    Time frame: From the date of all participants documented baseline data, until the date of the last participant documented the changes of biomarkers in peripheral blood, assessed up to 60 days

  2. The relative mRNA expression rate of the Nrf2- dependent ferroptosis genes in peripheral blood

    Biomarkers of the Nrf2- dependent ferroptosis

    Time frame: From the date of all participants documented baseline data, until the date of the last participant documented the changes of biomarkers in peripheral blood, assessed up to 60 days

  3. The relative mRNA expression rate of the iron metabolism genes in peripheral blood

    Biomarkers of the iron metabolism

    Time frame: From the date of all participants documented baseline data, until the date of the last participant documented the changes of biomarkers in peripheral blood, assessed up to 60 days

07

Study locations

1 of 1 sites recruiting
  • Wenjing Zhao
    Yangzhou, Jiangsu 225001, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2023 (actual). Primary completion is estimated for Aug 2023, 1 month after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2023
First posted
Jul 18, 2023
StartActual
Jul 1, 2023
Primary completionEst.
Aug 10, 2023
CompletionEst.
Sep 25, 2023
Last update
Jul 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05950386
Lead sponsor
Northern Jiangsu People's Hospital
Responsible party
WenJing Zhao (Principal Investigator, Northern Jiangsu People's Hospital) — Principal investigator
First posted
Jul 18, 2023
Start date
Jul 1, 2023
Primary completion
Aug 10, 2023 (estimated)
Completion
Sep 25, 2023 (estimated)
Last update
Jul 21, 2023

Study contacts

Ju Gao
Contact
gaoju_003@163.com
+8618118206088

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion